What is RNA editing and why would we use it instead of DNA editing?
RNA editing is a way to correct or modify genetic instructions at the RNA level, after they've been copied from DNA but before they're turned into protein. Think of it as editing a draft of a document rather than changing the original file. The most common type, adenosine-to-inosine (A-to-I) editing, is performed by naturally occurring enzymes called ADARs (adenosine deaminases acting on RNA) [9]. Because inosine is read as guanosine by the cell's protein-making machinery, this single-letter change can alter the protein produced.
The key advantage over DNA editing (like CRISPR) is reversibility and control. RNA editing is temporary—the RNA molecule degrades naturally, so the effect wears off. This makes it ideal for conditions where you want a short-term fix, such as treating acute pain, viral infections, or inflammation, without permanently altering the genome [7]. It also avoids the risk of unintended, permanent DNA changes that could cause cancer [11]. As one review notes, RNA editing offers 'precise and reversible modifications at the RNA level, complementing traditional DNA-targeting therapies' [6].
How close are we to actually using this in patients?
The first clinical trial application for an RNA editing therapy was filed in 2023 by Wave Life Sciences for a drug called WVE-006 to treat alpha-1 antitrypsin deficiency, a genetic lung and liver disease [12]. This marks a major milestone, moving from the lab bench to regulatory review. However, this is just the first step; the therapy still needs to pass through clinical trials to prove it is safe and effective in humans.
Beyond this single candidate, the field is actively solving the remaining hurdles. A major challenge is designing small guide RNAs (gRNAs) that can efficiently direct ADAR enzymes to the correct spot on the RNA. Many current gRNAs are too large for approved delivery methods [2]. Researchers have developed a selection assay to identify shorter, more efficient gRNAs, with eight out of ten top candidates showing superior editing in cells [2]. Another team engineered a chemically controlled 'on-off' switch for editing, achieving up to 44% correction of a target gene in cell culture, which could allow doctors to precisely time the therapy [1].
Delivery is another critical bottleneck. Getting the editing machinery into the right cells—especially outside the liver—remains difficult [4][8]. Lipid nanoparticles (LNPs), the technology used in mRNA COVID-19 vaccines, are being tested for RNA editing delivery, with one study showing they can deliver circular RNA vaccines that successfully reprogrammed the immune system to attack tumors in mice [5]. This suggests that delivery solutions are emerging, but they are not yet perfected for all tissues.
What are the biggest remaining challenges before this becomes a standard treatment?
Three main challenges stand out: specificity, delivery, and durability. First, ensuring the editing happens only at the intended RNA site and not elsewhere (off-target editing) is critical to avoid side effects. While newer systems like engineered circular guide RNAs have been shown to boost editing efficiency by 2- to 40-fold without compromising specificity in cell and animal studies [3], the risk of off-target effects remains a key concern [8].
Second, delivery to the right tissues is still a major hurdle. Most current delivery systems, like adeno-associated viruses (AAVs) and LNPs, naturally target the liver. Getting RNA editing tools into the brain, heart, or muscles requires new, tissue-specific delivery technologies [4][10]. As one review puts it, 'delivery systems and tissue specificity are determinant factors for in vivo therapeutic applications' [4].
Third, the durability of the effect is limited because RNA itself is short-lived. This is a feature for some applications (like treating acute pain) but a limitation for chronic diseases that would require repeated dosing. Researchers are exploring ways to extend the effect, for example by using circular RNAs that are more stable than linear ones [3][8]. The field is also grappling with how to scale up manufacturing and navigate regulatory frameworks for a completely new class of medicine [8].
About These Sources
This answer is built on 12 peer-reviewed studies — published from 2021 to 2026, 6 from 2024 or later, 7 in Q1 journals, collectively cited 277 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 76 papers retrieved from a database of over 500 million.
Sources used in this answer
Controlling Site‐Directed RNA Editing by Chemically Induced Dimerization
Demonstrated chemically controlled RNA editing in human cells, achieving up to 44% editing of a target gene and 42% repair of a disease-relevant mutation (MECP2 R106Q), enabling temporal control of the therapy.
Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing
Developed an in vitro selection assay to identify short, efficient guide RNAs for RNA editing; eight of the top ten short guides showed superior editing in cells, addressing a key hurdle for clinical use.
Engineered circular guide RNAs boost CRISPR/Cas12a- and CRISPR/Cas13d-based DNA and RNA editing
Engineered circular guide RNAs (cgRNAs) that boosted CRISPR/Cas12a and Cas13d editing efficiency by 2.1- to 40.2-fold in cells and in mouse liver, without reducing specificity.
DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects
A 2026 review summarizing that DNA and RNA editing tools are shifting medicine toward precision treatments, but key bottlenecks remain in delivery efficiency, tissue specificity, and safety assessment.
Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity
Provided proof-of-concept that site-directed RNA editing can generate neoantigens from shared tumor antigens; a circular RNA vaccine delivered via lipid nanoparticles suppressed tumor growth in mice.
Emerging clinical applications of ADAR based RNA editing
A 2025 review highlighting that ADAR-based RNA editing offers precise, reversible modifications and that initial clinical advancements are demonstrating its potential in human disease.
RNA editing: Expanding the potential of RNA therapeutics
A 2023 review arguing that RNA editing is particularly suited for transient therapeutic effects (e.g., pain, inflammation, viral infection) and for modulating protein function without permanent genome changes.
Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives
A 2025 review noting that while RNA therapeutics have revolutionized medicine, challenges like off-target effects, immune activation, and delivery to extrahepatic tissues remain to be solved.
RNA editing enzymes: structure, biological functions and applications
A 2024 review providing an overview of RNA editing enzymes (ADARs, APOBECs), their structures, biological roles in immunity and cancer, and their potential for correcting disease-causing mutations.
CRISPR-Cas technologies: Emerging tools from research to clinical application.
A 2025 review of CRISPR-Cas technologies stating that continued development of targeted delivery systems is required to amplify therapeutic efficiency and safety.
Cas-Based Systems for RNA Editing in Gene Therapy of Monogenic Diseases: In Vitro and in Vivo Application and Translational Potential
A 2022 review of Cas13-based RNA editing for monogenic diseases, noting that editing at the RNA level avoids the risk of DNA double-strand breaks, a key safety advantage.
Shoot the messenger: RNA editing is here
Reported that Wave Life Sciences plans to file a clinical trial application in 2023 for WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency, marking a first-in-human milestone.